Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome

European Journal of Medical Research

Volumn 12, Issue 5, 2007, Pages 216-221

  Wei, Jia Li ^a   Cui, Hui Ming ^b   Ma, Chun Yang ^c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Zhongshan People's Hospital   (China)

^c HAINAN MEDICAL UNIVERSITY   (China)

Author keywords

HMG CoA reductase inhibitors; Nephrotic syndrome; PAI 1; Tissue factor

Indexed keywords

CHROMOGENIC SUBSTRATE; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; SIMVASTATIN; THROMBOPLASTIN;

ADULT; ARTICLE; CELL ISOLATION; CELL SECRETION; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MALE; NEPHROTIC SYNDROME; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ADULT; FEMALE; GENE EXPRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKOCYTES, MONONUCLEAR; MALE; NEPHROTIC SYNDROME; PLASMINOGEN ACTIVATOR INHIBITOR 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIMVASTATIN; THROMBOPLASTIN;

EID: 34250612255     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Yoshida Y, Shiiki H, Iwano M, et al. Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome. Nephron 2001, 88(1):24-9
2. Ariens RA, Moia M, Rivolta E, et al. High levels of tissue factor pathway inhibitor in patients with nephrotic proteinuria. Thromb Haemost 1999,82(3):1020-3.
3. Malyszko JS,Malyszko J,Mysliwiec M. Tissue factor and inhibitor of the blood coagulation pathway in nephrotic syndrome.Pol Arch Med Wewn 1999,101(4):301-5.
4. Malyszko J,Malyszko JS, Pawlak D, et al. Comprehensive study on platelet function, hemostasis, fibrinolysis, peripheral serotonergic system and serum lipids in nephrotic syndrome.Pol J Pharmacol 1996,48(2):191-5.
5. Buemi M, Nostro L,Crasci E, Barilla A, et al. Statins in nephrotic syndrome: A new weapon against tissue injury. Med Res Rev 2005, 25(6):587-609.
6. Joyce M, Kelly C, Winter D, Chen G, Leahy A, Bouchier-Hayes D. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemiareperfusion. J Surg Res 2001,101: 79-84.
7. Lee SK, Jin SY,Han DC, Hwang SD,and Lee HB. Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in nephrectomized rats. Nephrol Dial Transplant 1993,8ÅF1338-1343.
8. Harris KP, Purkerson ML, Yates J, and Klahr S. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis 1990, 15: 16-23.
9. Moriyama T, Kawada N, Nagatoya K, Takeji M, Horio M, Ando A, Imai E, and Hori M. Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney Int 2001,59: 2095-2103.
10. Dorffel Y, Latsch C, Stuhlmuller B, Schreiber S, Scholze S, Burmester GR, Scholze J. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 1999, 34(1):113-7.
11. Almus FE, Mohan Rao LV, Pendurthi UR, Quattrochi L and Rapaport SI. Mechanism for diminished tissue factor expression by endothelial cells cultured with heparin binding growth factor-1 and heparin, Blood 1991,77: 1256-1262.
12. Nordt TK, Sawa H, Fujii S and Sobel BE. Induction plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo, Circulation 1995, 91:764-770.
13. Aikawa M, Voglic SJ, Sugiyama S, Rabkin E, Taubman MB and JFallon JT, et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma, Circulation 1999,100:1215-122.
14. Ushigome H, Sano H,Okamoto M, et al. The role of tissue factor in renal ischemic reperfusion injury of the rat. J Surg Res 2002, 102(2):102-9.
15. Matsuyama M, Yoshimura R, Akioka K, et al. Tissue factor antisense oligonucleotides prevent renal ischemia-reperfusion injury. Transplantation 2003, 76(5):786-91.
16. Mercier E, Branger B, Vecina F, et al. Tissue factor coagulation pathway and blood cells activation state in renal insufficiency. Hematol J 2001, 2(1):18-25.
17. Wendt T, Zhang YM, Bierhaus A, et al. Tissue factor expression in an animal model of hydronephrosis. Nephrol Dial Transplant1995, 10(10):1820-8.
18. Cunningham MA, Ono T, Hewitson TD, et al. Tissue factor pathway inhibitor expression in human crescentic glomerulonephritis. Kidney Int1995, 5(4):1311-8.
19. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002, 283: F209-F220.
20. Paukesakon P, Revelo MP, Marcantoni C, Fogo AB. Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy. Kidney Int 2002, 61: 2142-2148.
21. Revelo MP, Federspiel C, Helderman H, et al. Chronic allograft nephropathy: expression and localization of PAI-1 and PPAR-gamma. Nephrol Dial Transplant 2005,20 (12):2812-9.
22. Fogo AB. The role of angiotensin II and plasminogen activator-inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 2000, 35: 179-188.
23. Lee HB, Ha H. Plasminogen activator inhibitor-1 and diabetic nephropathy. Nephrology 2005, 10 Suppl:S11-3.
24. Matsuo S, Lopez-Guisa JM, Cai X, et al. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1- overexpressing mice. Kidney Int 2005, 67(6): 2221-38.
25. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat. Med 2002, 8:1257-1262.
26. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc. Res 2000,47:648-657.
27. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler. Thromb. Vasc. Biol 2001, 21:1712-1719.
28. Bea F, Blessing E, Bennett B, Levitz M, Wallace EP and Rosenfeld ME. Simvastatin promotes atherosclerotic plaque stability in ApoE-deficient mice independently of lipid lowering. Arterioscler. Thromb. Vasc. Biol 2002, 22:1832-1837.
29. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int 1999, Suppl 71:S2-5.
30. Li C, Yang CW, Park JH, Lim SW, Sun BK, Jung JY, Kim SB, Kim YS, Kim J, Bang BK. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 2004, 286 (1):F46-57.
31. Wiesbauer F, Kaun C and Zorn G, et al. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol 2002, 135:284-292.
32. Haslinger B, Kleemann R and Toet KH, et al. Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-[alpha]-activated human peritoneal mesothelial cells, Kidney Int 2003,63: 2065-2074.
33. Lang D,Terstesse M, Dohle F, et al. Protein kinase C (PKC) dependent induction of tissue factor (TF) by mesangial cells in response to inflammatory mediators and release during apoptosis.Br J Pharmacol 2002,137(7): 1116-24.
34. Neve BP, Corseaux D, Chinetti G, et al. PPARα agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2001,103(2): 207-212.